211 related articles for article (PubMed ID: 15281092)
1. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Sgambato A; Camerini A; Faraglia B; Ardito R; Bianchino G; Spada D; Boninsegna A; Valentini V; Cittadini A
J Cell Physiol; 2004 Oct; 201(1):97-105. PubMed ID: 15281092
[TBL] [Abstract][Full Text] [Related]
2. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Di Gennaro E; Barbarino M; Bruzzese F; De Lorenzo S; Caraglia M; Abbruzzese A; Avallone A; Comella P; Caponigro F; Pepe S; Budillon A
J Cell Physiol; 2003 Apr; 195(1):139-50. PubMed ID: 12599217
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
Mimeault M; Jouy N; Depreux P; Hénichart JP
Prostate; 2005 Feb; 62(2):187-99. PubMed ID: 15389789
[TBL] [Abstract][Full Text] [Related]
4. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells.
Ye D; Mendelsohn J; Fan Z
Clin Cancer Res; 1999 Aug; 5(8):2171-7. PubMed ID: 10473102
[TBL] [Abstract][Full Text] [Related]
5. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Campiglio M; Locatelli A; Olgiati C; Normanno N; Somenzi G; Viganò L; Fumagalli M; Ménard S; Gianni L
J Cell Physiol; 2004 Feb; 198(2):259-68. PubMed ID: 14603528
[TBL] [Abstract][Full Text] [Related]
7. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
[TBL] [Abstract][Full Text] [Related]
8. ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
Yabuuchi S; Katayose Y; Oda A; Mizuma M; Shirasou S; Sasaki T; Yamamoto K; Oikawa M; Rikiyama T; Onogawa T; Yoshida H; Ohtuska H; Motoi F; Egawa S; Unno M
Anticancer Res; 2009 Apr; 29(4):1169-80. PubMed ID: 19414361
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Matheny KE; Barbieri CE; Sniezek JC; Arteaga CL; Pietenpol JA
Laryngoscope; 2003 Jun; 113(6):936-9. PubMed ID: 12782800
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Vicentini C; Festuccia C; Gravina GL; Angelucci A; Marronaro A; Bologna M
J Cancer Res Clin Oncol; 2003 Mar; 129(3):165-74. PubMed ID: 12712332
[TBL] [Abstract][Full Text] [Related]
11. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism.
Lee EJ; Whang JH; Jeon NK; Kim J
Ann N Y Acad Sci; 2007 Jan; 1095():113-28. PubMed ID: 17404024
[TBL] [Abstract][Full Text] [Related]
12. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Jänne PA; Taffaro ML; Salgia R; Johnson BE
Cancer Res; 2002 Sep; 62(18):5242-7. PubMed ID: 12234991
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
Chang GC; Hsu SL; Tsai JR; Liang FP; Lin SY; Sheu GT; Chen CY
Biochem Pharmacol; 2004 Oct; 68(7):1453-64. PubMed ID: 15345335
[TBL] [Abstract][Full Text] [Related]
15. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Shintani S; Kiyota A; Mihara M; Sumida T; Kayahara H; Nakashiro K; Hamakawa H
Am J Clin Oncol; 2003 Oct; 26(5):e150-6. PubMed ID: 14528090
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
18. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Zi X; Grasso AW; Kung HJ; Agarwal R
Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Bianco C; Tortora G; Bianco R; Caputo R; Veneziani BM; Caputo R; Damiano V; Troiani T; Fontanini G; Raben D; Pepe S; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Oct; 8(10):3250-8. PubMed ID: 12374696
[TBL] [Abstract][Full Text] [Related]
20. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]